PEPG
Pepgen Inc.
A clinical-stage biotech working to treat severe neuromuscular diseases, PepGen builds "oligonucleotide" medicines designed to fix faulty genetic instructions, using its EDO platform of cell-penetrating peptides to ferry drugs into muscle and other hard-to-reach tissues. Its lead candidate, PGN-EDODM1, targets myotonic dystrophy type 1 and has earned Orphan Drug and Fast Track designations. Founded in 2018, the company's name combines "Pep" for its peptide delivery technology and "Gen" for the genetic diseases it tackles.
CUSIP: 713317105HealthcareUS1 holder
Total Value
$6.27M
Total Shares
3.48M
Net Share Change
0
Activity
No changes
Investor
Value
Shares
Weight
Change
